Mick Hartley

See also, this open letter from clinicians to Wes Streeting:

We think that PATHWAYS Trial is unsafe, doesn’t meet the requirements of UK clinical trial regulations, and should not proceed for the following reasons:

1. The expected benefits do not outweigh the expected risks, jeopardising the safety and wellbeing of participants.
2. Foreseeable risks to child development are not minimized.
3. The trial is not scientifically sound.
4. Important information from people who have already received gonadotrophin-releasing hormone analogues (GnRHa) (the Data Linkage Study) should be evaluated first.